First Time Loading...
C

Clarity Pharmaceuticals Ltd
ASX:CU6

Watchlist Manager
Clarity Pharmaceuticals Ltd
ASX:CU6
Watchlist
Price: 3.65 AUD 11.62% Market Closed
Updated: May 4, 2024
Section:
 

Wall Street
Price Targets

CU6 Price Targets Summary
Clarity Pharmaceuticals Ltd

Wall Street analysts forecast CU6 stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CU6 is 3.43 AUD with a low forecast of 3.12 AUD and a high forecast of 4.08 AUD.

CU6 Lowest Forecast
Wall Street Target
3.12 AUD
14% Downside
CU6 Average Forecast
Wall Street Target
3.43 AUD
6% Downside
CU6 Highest Forecast
Wall Street Target
4.08 AUD
12% Upside
Lowest
Price Target
3.12 AUD
14% Downside
Average
Price Target
3.43 AUD
6% Downside
Highest
Price Target
4.08 AUD
12% Upside
Clarity Pharmaceuticals Ltd Competitors:
Price Targets
CORT
Corcept Therapeutics Inc
78% Upside
VLS
Vita Life Sciences Ltd
62% Downside
H
293480
Hana Pharm Co Ltd
52% Upside
Y
002019
Yifan Pharmaceutical Co Ltd
24% Upside
CORT
Corcept Therapeutics Inc
78% Upside
VLS
Vita Life Sciences Ltd
62% Downside
H
293480
Hana Pharm Co Ltd
52% Upside
Y
002019
Yifan Pharmaceutical Co Ltd
24% Upside
PAHC
Phibro Animal Health Corp
36% Downside
BOI
Boiron SA
28% Upside
TLRY
Tilray Brands Inc
15% Upside
SANOFI
Sanofi India Ltd
9% Upside

Revenue
Forecast

Revenue Estimate
Clarity Pharmaceuticals Ltd

For the last 2 years the compound annual growth rate for Clarity Pharmaceuticals Ltd's revenue is 88%. The projected CAGR for the next 3 years is 110%.

88%
Past Growth
110%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Clarity Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Clarity Pharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
CU6 intrinsic value, competitors valuation, and company profile.
DCF Valuation
CU6 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CU6 stock valuation using valuation multiples.
Wall Street Estimates
CU6 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CU6 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CU6's stock price target?
Price Target
3.43 AUD

According to Wall Street analysts, the average 1-year price target for CU6 is 3.43 AUD with a low forecast of 3.12 AUD and a high forecast of 4.08 AUD.

What is Clarity Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
110%

For the last 2 years the compound annual growth rate for Clarity Pharmaceuticals Ltd's revenue is 88%. The projected CAGR for the next 3 years is 110%.

ALPHA SPREAD
Join more than 134,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.